Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Tedizolid is a new oxazolidinone with improved and intracellular potency against , including multidrug-resistant strains, and some species of nontuberculous mycobacteria (NTM) compared with that of linezolid. Using the current Clinical and Laboratory Standards Institute (CLSI)-recommended method of broth microdilution, susceptibility testing of 170 isolates of rapidly growing mycobacteria showed equivalent or lower (1- to 8-fold) MIC and/or MIC values for tedizolid compared with that for linezolid. The tedizolid MIC values for 81 isolates of subsp. and 12 isolates of subsp. were 8 μg/ml and 4 μg/ml, respectively, compared with linezolid MIC values of 32 μg/ml for both. The MIC values for 20 isolates of were 2 μg/ml for tedizolid and 4 μg/ml for linezolid. Twenty-two isolates of had tedizolid and linezolid MICs of 2 μg/ml and 16 μg/ml, respectively. One hundred forty-two slowly growing NTM, including 7/7 , 7/7 , and 7/11 of other less commonly isolated species, had tedizolid MICs of ≤1 μg/ml and linezolid MICs of ≤4 μg/ml. One hundred isolates of complex and eight isolates had tedizolid MICs of 8 μg/ml and linezolid MICs 32 and 64 μg/ml, respectively. Nine isolates had MICs of 4 μg/ml and 16 μg/ml for tedizolid and linezolid, respectively. These findings demonstrate a greater potency of tedizolid than linezolid against NTM and suggest that an evaluation of tedizolid as a potential treatment agent for infections caused by selected NTM is warranted.